Aastrom Announces Appointment of Gerard Michel as Chief Financial Officer and Vice President, Corporate Development
June 04 2014 - 8:45AM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of
patient-specific expanded cellular therapies for the treatment of
severe diseases and conditions, today announced the appointment of
Gerard Michel, MS, MBA, as chief financial officer and vice
president, corporate development.
Mr. Michel was formerly chief financial officer and vice
president, corporate development of Biodel, where he oversaw
strategic development, fundraising and capital structure
management, marketing efforts, investor relations, and financial
reporting and internal controls.
Prior to his role at Biodel, Mr. Michel served as chief
financial officer and vice president of corporate development of
NPS Pharmaceuticals, where he led the first syndicated royalty
monetization, the structure of which has been widely copied and
used to create new sources of capital for biotechnology
companies.
"With his considerable experience in business development,
raising capital and executing successful financial transactions,
Gerard significantly strengthens our senior team in finance,
investor relations and corporate development," said Nick Colangelo,
president and chief executive officer of Aastrom. "Gerard has
successfully led many efforts to secure top-tier financing and has
raised hundreds of millions of dollars throughout his career. He
also brings extensive experience in corporate management and in
positioning company assets for advantageous licensing and
partnering opportunities. We look forward to having his insights
and expertise as we focus on advancing Aastrom's business strategy
in the years ahead."
About Aastrom Biosciences
Aastrom Biosciences is the leader in developing patient-specific
expanded cellular therapies for use in the treatment of patients
with severe diseases and conditions. Aastrom markets three
autologous cell therapy products in the United States and European
Union for the treatment of cartilage repair and skin replacement,
and is developing ixmyelocel-T, a patient-specific multicellular
therapy for the treatment of advanced heart failure due to ischemic
dilated cardiomyopathy. For more information, please visit
Aastrom's website at www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements, including,
without limitation, statements concerning clinical trial plans and
progress, objectives and expectations, clinical activity timing,
intended product development, anticipated milestones, potential
advantages of our product candidates and the commercial success of
our products, all of which involve certain risks and uncertainties.
These statements are often, but are not always, made through the
use of words or phrases such as "anticipates," "intends,"
"estimates," "plans," "expects," "we believe," "we intend," and
similar words or phrases, or future or conditional verbs such as
"will," "would," "should," "potential," "could," "may," or similar
expressions. Actual results may differ significantly from the
expectations contained in the forward-looking statements. Among the
factors that may result in differences are the inherent
uncertainties associated with the clinical trial and product
development activities, regulatory approval requirements,
competitive developments, product commercialization and the
availability of resources and the allocation of resources among
different potential uses. These and other significant factors
are discussed in greater detail in Aastrom's Annual Report on Form
10-K for the year ended December 31, 2013, filed with the
Securities and Exchange Commission ("SEC") on March 13, 2014,
Quarterly Reports on Form 10-Q and other filings with the SEC.
These forward-looking statements reflect management's current views
and Aastrom does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release
except as required by law.
CONTACT: Media contact:
David Salisbury
Berry & Company
dsalisbury@berrypr.com
(212) 253-8881
Investor contact:
Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024